Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chul Ahn
Daniel Ahn

Showing results (531-540 of 593) with videos related to

Pageof 60
Sort By:
Angewandte Chemie (International Ed. in English)|January 31, 2018
Conformation-Enabled Total Syntheses of Ohmyungsamycins A and B and Structural Revision of Ohmyungsamycin BJoonseong Hur, Jaebong Jang, Jaehoon Sim, et al.
Journal of Medicinal Chemistry|April 6, 2017
N<sup>6</sup>-Substituted 5'-N-Methylcarbamoyl-4'-selenoadenosines as Potent and Selective A<sub>3</sub> Adenosine Receptor Agonists with Unusual Sugar Puckering and Nucleobase OrientationJinha Yu, Long Xuan Zhao, Jongmi Park, et al.
Cancer Research|August 3, 2002
The N-ras proto-oncogene can suppress the malignant phenotype in the presence or absence of its oncogeneRoberto Diaz, Daniel Ahn, Lluis Lopez-Barcons, et al.
Practical Radiation Oncology|November 18, 2024
Financial Toxicity and Quality-of-Life Outcomes on a Phase 1 5-fraction Stereotactic Partial Breast Irradiation Protocol for Early-Stage Breast CancerAmbrosia Simmons, David Sher, Dr Dong Wook Nathan Kim, et al.
World Journal of Clinical Oncology|September 13, 2023
Targeting <i>KRAS</i> in pancreatic adenocarcinoma: Progress in demystifying the holy grailAhmed Elhariri, Ahmed Alhaj, Daniel Ahn, et al.
Contemporary Clinical Trials|January 14, 2024
Preventing cognitive decline by reducing BP target (PCOT): A randomized, pragmatic, multi-health systems clinical trialJohn M Giacona, Brooke M Bates, Venkatraghavan Sundaram, et al.
Cancers|February 24, 2024
Drug Response of Patient-Derived Lung Cancer Cells Predicts Clinical Outcomes of Targeted TherapySunshin Kim, Youngjoo Lee, Bo Ram Song, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 1, 2016
Systemic Immune Activity Predicts Overall Survival in Treatment-Naïve Patients with Metastatic Pancreatic CancerMatthew R Farren, Thomas A Mace, Susan Geyer, et al.
International Journal of Radiation Oncology, Biology, Physics|May 29, 2020
Risk Factors for Fat Necrosis After Stereotactic Partial Breast Irradiation for Early-Stage Breast Cancer in a Phase 1 Clinical TrialAsal Rahimi, Yuanyuan Zhang, Dong W Kim, et al.
Scientific Reports|December 29, 2019
Patient-Derived Cells to Guide Targeted Therapy for Advanced Lung AdenocarcinomaSeok-Young Kim, Ji Yeon Lee, Dong Hwi Kim, et al.
Pageof 60

Showing results (531-540 of 593) with videos related to

Sort By:
Pageof 60
Angewandte Chemie (International Ed. in English)|January 31, 2018
Conformation-Enabled Total Syntheses of Ohmyungsamycins A and B and Structural Revision of Ohmyungsamycin BJoonseong Hur, Jaebong Jang, Jaehoon Sim, et al.
Journal of Medicinal Chemistry|April 6, 2017
N<sup>6</sup>-Substituted 5'-N-Methylcarbamoyl-4'-selenoadenosines as Potent and Selective A<sub>3</sub> Adenosine Receptor Agonists with Unusual Sugar Puckering and Nucleobase OrientationJinha Yu, Long Xuan Zhao, Jongmi Park, et al.
Cancer Research|August 3, 2002
The N-ras proto-oncogene can suppress the malignant phenotype in the presence or absence of its oncogeneRoberto Diaz, Daniel Ahn, Lluis Lopez-Barcons, et al.
Practical Radiation Oncology|November 18, 2024
Financial Toxicity and Quality-of-Life Outcomes on a Phase 1 5-fraction Stereotactic Partial Breast Irradiation Protocol for Early-Stage Breast CancerAmbrosia Simmons, David Sher, Dr Dong Wook Nathan Kim, et al.
World Journal of Clinical Oncology|September 13, 2023
Targeting <i>KRAS</i> in pancreatic adenocarcinoma: Progress in demystifying the holy grailAhmed Elhariri, Ahmed Alhaj, Daniel Ahn, et al.
Contemporary Clinical Trials|January 14, 2024
Preventing cognitive decline by reducing BP target (PCOT): A randomized, pragmatic, multi-health systems clinical trialJohn M Giacona, Brooke M Bates, Venkatraghavan Sundaram, et al.
Cancers|February 24, 2024
Drug Response of Patient-Derived Lung Cancer Cells Predicts Clinical Outcomes of Targeted TherapySunshin Kim, Youngjoo Lee, Bo Ram Song, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 1, 2016
Systemic Immune Activity Predicts Overall Survival in Treatment-Naïve Patients with Metastatic Pancreatic CancerMatthew R Farren, Thomas A Mace, Susan Geyer, et al.
International Journal of Radiation Oncology, Biology, Physics|May 29, 2020
Risk Factors for Fat Necrosis After Stereotactic Partial Breast Irradiation for Early-Stage Breast Cancer in a Phase 1 Clinical TrialAsal Rahimi, Yuanyuan Zhang, Dong W Kim, et al.
Scientific Reports|December 29, 2019
Patient-Derived Cells to Guide Targeted Therapy for Advanced Lung AdenocarcinomaSeok-Young Kim, Ji Yeon Lee, Dong Hwi Kim, et al.
Pageof 60